
GLP-1 medications show broad potential to curb multiple addictions
A BMJ study analyzing VA records of over 600,000 adults with type 2 diabetes found that GLP-1 drugs (such as semaglutide and tirzepatide) were associated with fewer emergency visits, hospitalizations, and deaths related to substance use across alcohol, opioids, nicotine, and other drugs. Using emulated target trials, researchers suggest GLP-1s might help treat existing substance use disorders and potentially prevent new ones, possibly by dampening reward signaling in the brain. However, these are observational analyses, not randomized trials, and results may not apply to everyone; further trials are underway, with relapse and varied efficacy remaining challenges.












